Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy.
Adult
B-Lymphocytes
/ immunology
Case-Control Studies
Cohort Studies
Colitis, Ulcerative
/ blood
Combined Modality Therapy
Crohn Disease
/ blood
Female
Humans
Immune System
/ pathology
Immunophenotyping
Inflammatory Bowel Diseases
/ blood
Male
Mercaptopurine
/ therapeutic use
Middle Aged
Severity of Illness Index
Surveys and Questionnaires
T-Lymphocytes
/ immunology
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Anti-TNF
CyTOF
FACS
Immunophenotype
Thiopurine
Journal
Cellular and molecular gastroenterology and hepatology
ISSN: 2352-345X
Titre abrégé: Cell Mol Gastroenterol Hepatol
Pays: United States
ID NLM: 101648302
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
06
2020
revised:
24
03
2021
accepted:
24
03
2021
pubmed:
5
4
2021
medline:
28
1
2022
entrez:
4
4
2021
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is a complex disease with variable presentation, progression, and response to therapies. Current disease classification is based on subjective clinical phenotypes. The peripheral blood immunophenome can reflect local inflammation, and thus we measured 39 circulating immune cell types in a large cohort of IBD and control subjects and performed immunotype:phenotype associations. We performed fluorescence-activated cell sorting or CyTOF analysis on blood from 728 Crohn's disease, 464 ulcerative colitis, and 334 non-IBD patients, with available demographics, endoscopic and clinical examinations and medication use. We observed few immune cell types commonly affected in IBD (lowered natural killer cells, B cells, and CD45RA We present a peripheral map of immune cell changes in IBD related to disease entity and therapies as a resource for hypothesis generation. We propose the changes in B cell subsets could affect antibody formation and potentially explain the mechanism behind the superiority of combination therapy through the impact of thiopurines on pharmacokinetics of anti-TNFs.
Sections du résumé
BACKGROUND
Inflammatory bowel disease (IBD) is a complex disease with variable presentation, progression, and response to therapies. Current disease classification is based on subjective clinical phenotypes. The peripheral blood immunophenome can reflect local inflammation, and thus we measured 39 circulating immune cell types in a large cohort of IBD and control subjects and performed immunotype:phenotype associations.
METHODS
We performed fluorescence-activated cell sorting or CyTOF analysis on blood from 728 Crohn's disease, 464 ulcerative colitis, and 334 non-IBD patients, with available demographics, endoscopic and clinical examinations and medication use.
RESULTS
We observed few immune cell types commonly affected in IBD (lowered natural killer cells, B cells, and CD45RA
CONCLUSIONS
We present a peripheral map of immune cell changes in IBD related to disease entity and therapies as a resource for hypothesis generation. We propose the changes in B cell subsets could affect antibody formation and potentially explain the mechanism behind the superiority of combination therapy through the impact of thiopurines on pharmacokinetics of anti-TNFs.
Identifiants
pubmed: 33813036
pii: S2352-345X(21)00064-3
doi: 10.1016/j.jcmgh.2021.03.012
pmc: PMC8263768
pii:
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Mercaptopurine
E7WED276I5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-632Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.